Building the Next AlphaFold for Drug Discovery
@IsomorphicLabs closed a $2.1 billion Series B to commercialize AlphaFold — but Charlotte Deane's argument in this clip is that the next equivalent breakthrough is still waiting on the data infrastructure to make it possible.
Deane makes a point that tends to get lost in the excitement around model capabilities: AlphaFold succeeded in large part because the Protein Data Bank existed, an accumulated fifty years of experimental results that gave AI something substantive to learn from. Her
@openBIND consortium is an attempt to replicate that condition deliberately — building the dataset for protein-ligand binding with AI requirements built in from the start, not discovered after the fact. The $2.1 billion now flowing into AI drug discovery, as reported by
@BuildFastWithAI, will accelerate what is already possible with existing data, but Deane's work is about removing the ceiling on what comes next.
For institutional decision-makers evaluating where durable value is being created in this space, the more consequential investment question may not be which model is best today, but who is building the data infrastructure that determines what models can do in five years.
We've put a link to the full episode with Charlotte Deane and our hosts
@stephenjhorn and
@Laila_Rizvi in the first comment.
#BiomedicalDataScience #AIMedicine #ComputationalBiology #AlphaFold #AIDrugDiscovery